RGCC and diffuse large B-cell lymphoma: Survival analysis via Kaplan-Meier curves revealed that DLBCL patients with elevated RGC32 expression exhibited significantly reduced progression-free survival (PFS; p = 0.015) and overall survival (OS; p = 0.035) compared to RGC32-negative counterparts (Figure 1B).